Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic

As the management of patients with ESR1-mutated metastatic breast cancer evolves, various questions have emerged in clinical practice. “It's a complex situation,” explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women's Cancers Program director at the City of Hope Comprehensive Cancer Center in Duarte, California. She discusses how recent advances have changed treatment decisions with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. “I think it's important to keep in mind that today we just have single-agent oral SERDs, and people like to give combinations,” Dr. Rugo notes. But what combinations to give and when remains unclear. “I think how we're going to decide is that we're going to wait and see what's approved and then look at patients to try and figure out what to do,” she offers.